Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Bodziock

Cardiovascular Disease Winston Salem, NC Medical Doctor

NPI 1316392665 CMS profile 7225892

Medical Center Blvd, Winston Salem, NC 27157

Open in the dashboard

General payments

$53,707

230 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Bodziock of Winston Salem, NC is reported in the CMS Open Payments database as having received $53,707 across 230 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,737 38
2024 General $19,752 117
2023 General $4,117 24
2022 General $25,174 41
2021 General $411 3
2020 General $338 4
2019 General $178 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Bodziock
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to George Bodziock were reported at $3,737. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year George Bodziock Cardiovascular Disease median Middle half National median
2019 $178 $450 $127–$1,392 $163
2020 $338 $242 $77–$751 $114
2021 $411 $335 $101–$1,037 $132
2022 $25,174 $395 $121–$1,211 $149
2023 $4,117 $443 $136–$1,283 $160
2024 $19,752 $450 $136–$1,323 $164
2025 $3,737 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $30,772 84 payments
  2. Abbott Laboratories $7,892 67 payments
  3. Boston Scientific Corporation $5,829 34 payments
  4. Philips Electronics North America Corporation $5,615 11 payments
  5. Biosense Webster, Inc. $2,090 17 payments
  6. Biotronik Inc. $1,063 10 payments
  7. AstraZeneca Pharmaceuticals LP $199 2 payments
  8. Atricure, Inc. $168 2 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $66 2 payments
  10. Amgen Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $21,500 2 payments
  2. Travel and Lodging $21,205 69 payments
  3. Food and Beverage $7,600 145 payments
  4. Education $2,027 12 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $900 1 payment
  6. Consulting Fee $475 1 payment
Products named General payments · program years 2019–2025
  1. (9520) IGT Devices Undivided $4,851 1 payment
  2. Micra $3,413 30 payments
  3. AVEIR Cardiac Rhythm Management $3,039 16 payments
  4. ENSITE PRECISION $2,557 30 payments
  5. General - Therapies $2,423 10 payments
  6. Carto 3 $1,713 13 payments
  7. AVEIR Cardiac Rhythm Management $1,194 6 payments
  8. EVERA MRI XT DR SURESCAN $898 2 payments
  9. VersaCross Access Solution $764 5 payments
  10. PAMIRA $704 3 payments
  11. Other $4,933 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

132

Median for Cardiology: 2,533

Drug cost

$37,865

Median for Cardiology: $485,213

Branded share of claims

22.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 30 $35,756
Dofetilide Generic 13 $810
Flecainide Acetate Generic 26 $583
Amiodarone Hcl Generic 15 $279
Metoprolol Succinate Generic 16 $278
Metoprolol Tartrate Generic 20 $108
Cephalexin Generic 12 $52

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$42,881

Medicare's payments for the services billed

Medicare patients

140

Average age 76

Services billed

210

63 women, 77 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Ischemic heart disease 57%
Heart failure 51%
Arthritis 46%
Diabetes 41%
Chronic kidney disease 35%
Depression 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

230 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record